Bibliography
Found 12 results
Filters: Keyword is CD4 Lymphocyte Count and Author is Letendre, Scott L [Clear All Filters]
Better executive function is independently associated with full HIV suppression during combination therapy. AIDS. 2019 ;33(15):2309-2316.
. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.
Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis. 2017 ;215(1):105-113.
Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016 ;22(2):170-8.
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 ;23(1):83-7.
Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. Journal of Neurovirology [Internet]. 2007 ;13:150-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17505983
. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain: A Journal of Neurology [Internet]. 2006 ;129:1872-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16735456
Lithium improves HIV-associated neurocognitive impairment. AIDS (London, England) [Internet]. 2006 ;20:1885-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16954730
.